Artificial intelligence and computational methods are increasingly transforming biotech research and drug discovery. Notably, Insilico Medicine designed novel pan-KRAS inhibitors leveraging its AI-powered Chemistry42 platform, overcoming long-standing challenges in targeting KRAS mutations. Xaira Therapeutics, an AI-driven biotech unicorn, released the largest Perturb-seq dataset to date, facilitating detailed cellular response modeling. Intelliseq and Genomenon partnered to integrate cancer genomics knowledgebases into scalable clinical interpretation platforms. Such breakthroughs underscore AI’s growing role in enabling precision medicine and expediting therapeutic development.